SchilteM.N., LoureiroJ., KeuningE.D., ter WeeP.M., CelieJ.W.A.M., BeelenR.H.J.Long-term intervention with heparins in a rat model of peritoneal dialysis.Perit Dial Int2009; 29: 26–35.
2.
LindahlU.‘Heparin’—from anticoagulant drug into the new biology.Glycoconj J2000; 17: 597–605.
3.
LinhardtR.J.2003 Claude S. Hudson Award Address in Carbohydrate Chemistry. Heparin: structure and activity.J Med Chem2003; 46: 2551–64.
4.
FalangaA., MarchettiM.Heparin in tumor progression and metastatic dissemination.Semin Thromb Hemost2007; 33: 688–94.
5.
NiersT.M., KlerkC.P., DiNisioM., Van NoordenC.J., BullerH.R., ReitsmaP.H.Mechanisms of heparin induced anticancer activity in experimental cancer models.Crit Rev Oncol Hematol2007; 61: 195–207.
6.
MousaS.A.Heparin, low molecular weight heparin, and derivatives in thrombosis, angiogenesis, and inflammation: emerging links.Semin Thromb Hemost2007; 33: 524–33.
7.
SandsetP.M., BendzB., HansenJ.B.Physiological function of tissue factor pathway inhibitor and interaction with heparins.Haemostasis2000; 30(Suppl 2): 48–56.
8.
DzieciuchowiczL., ChecinskiP., KraussH.Heparin reduces oxidative stress in the postoperative period.Med Sci Monit2002; 8: CR657–60.
De VrieseA.S., MortierS., LameireN.H.Non anticoagulant effects of heparin: implications for animal models of peritoneal dialysis.Perit Dial Int2001; 21(Suppl 3): S354–6.
11.
DaviesS.J.Longitudinal relationship between solute transport and ultrafiltration capacity in peritoneal dialysis patients.Kidney Int2004; 66: 2437–45.
12.
BrimbleK.S., WalkerM., MargettsP.J., KundhalK.K., RabbatC.G.Meta-analysis: peritoneal membrane transport, mortality, and technique failure in peritoneal dialysis.J Am Soc Nephrol2006; 17: 2591–8.
13.
LaurensN., KoolwijkP., de MaatM.P.Fibrin structure and wound healing.J Thromb Haemost2006; 4: 932–9.
ManalaysayM.T., KumanoK., HyodoT., SakaiT.Inhibition of mesothelial cell growth and protein synthesis by heparin.Adv Perit Dial1995; 11: 239–42.
16.
TsaiT.J., YenC.J., FangC.C., YangC.C., LeeP.H., YenT.S.Effect of intraperitoneally administered agents on human peritoneal mesothelial cell growth.Nephron1995; 71: 23–8.
17.
PawlaczykK., Kuzlan-PawlaczykM., AnderstamB., HeimburgerO., BergstromJ., WaniewskiJ.Effects of intraperitoneal heparin on peritoneal transport in a chronic animal model of peritoneal dialysis.Nephrol Dial Transplant2001; 16: 669–71.
18.
BazarganiF., AlbrektssonA., YahyapourN., BraideM.Low molecular weight heparin improves peritoneal ultrafiltration and blocks complement and coagulation.Perit Dial Int2005; 25: 394–404.
19.
De VrieseA.S., MortierS., CornelissenM., PalmansE., VanackerN.J., LeyssensA.The effects of heparin administration in an animal model of chronic peritoneal dialysate exposure.Perit Dial Int2002; 22: 566–72.
20.
ZareieM., KeuningE.D., ter WeeP.M., BeelenR.H., van den BornJ.Improvement of a chronic rat model for peritoneal dialysis by using heparin-coated catheters.Adv Perit Dial2004; 20: 150–4.
21.
KimY.L., ChoS., KimJ.C., ChoD.K., KimY.J., LarmO.Effect in a rat model of heparinized peritoneal dialysis catheters on bacterial colonization and the healing of the exit site.Perit Dial Int2001; 21(Suppl 3): S357–8.
22.
SjolandJ.A., SmithP.R., JespersenJ., GramJ.Intraperitoneal heparin reduces peritoneal permeability and increases ultrafiltration in peritoneal dialysis patients.Nephrol Dial Transplant2004; 19: 1264–8.
23.
SjolandJ.A., PedersenR.S., JespersenJ., GramJ.Intraperitoneal heparin ameliorates the systemic inflammatory response in PD patients.Nephron Clin Pract2005; 100: c105–10.
24.
MizuiriS., MiyataS., SakaiK., KobayashiM., MiyagiM., NakanishiT.Effect of intraperitoneal administration of heparin on advanced glycation end-products in CAPD.Perit Dial Int1999; 19: 361–5.
25.
PonceS.P., BarataJ.D., SantosJ.R.Interference of heparin with peritoneal solute transport.Nephron1985; 39: 47–9.
26.
DemirkanF., AkarsuM., SifilA., TutucuK.N.Effect of intraperitoneal administration of low-molecular-weight heparin on plasma tissue factor pathway inhibitor levels in CAPD patients.Nephron2002; 91: 162–3.
27.
GoelS., MisraM., SaranR., KhannaR.The rationale for, and role of, heparin in peritoneal dialysis.Adv Perit Dial1998; 14: 111–15.
28.
FarooqV., HegartyJ., ChandrasekarT., LamertonE.H., MitraS., HoughtonJ.B.Serious adverse incidents with the usage of low molecular weight heparins in patients with chronic kidney disease.Am J Kidney Dis2004; 43: 531–7.
29.
KishimotoT.K., ViswanathanK., GangulyT., ElankumaranS., SmithS., PelzerK.Contaminated heparin associated with adverse clinical events and activation of the contact system.N Engl J Med2008; 358: 2457–67.
